Wei Li

Dr. Wei Li


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 November 2017 in Knowledge Management Research & Practice
Verified
Journal Article
Closed access
PDF file
WLWei Li
Wei Li
This paper establishes an impact factor model among government R&D input, enterprise R&D input and IPRP in China. It uses data from 1992 to 2012 for regression analysis and finds that government R&D i

14 November 2022 in Human Gene Therapy
Verified
Journal Article
Closed access
YCYichao Chen
Yichao Chen
STShuren Tao
Shuren Tao
JCJiajv CHEN
Jiajv CHEN
WLWei Li
Wei Li
This article systematically discusses Chinese current legal status and rules for human embryo gene editing in both administrative law and criminal law after several legislative modifications, and further systematically evaluates the values and the defects of these modifications. After He Jiankui's case, Chinese legislators devoted themselves to improve human embryo gene editing legislation. As a result, human embryo gene editing's legal status becomes more determined. Rules for human embryo gene editing in Chinese administrative law have gradually become a complete system centering on “ CBL-regulation ,” and the promulgation of Amendment (XI) to the Criminal Law reconciles the controversy existed in academic circles. Chinese rules for human embryo gene editing are moving from “doubtful development” to “complete legal system.”

1 August 2014 in Biotechnology Law Report
Verified
Journal Article
Closed access
XYXiang Yu
Xiang Yu
WLWei Li
Wei Li

16 December 2021 in Human Gene Therapy
Verified
Journal Article
Closed access
WLWei Li
Wei Li
JCJiajv CHEN
Jiajv CHEN
China has made efforts toward the preservation and utilization of human genetic resources (HGRs). In recent years, in the face of various issues that have become increasingly prominent in HGR research, China has continuously strengthened legislation and ethics, and has initially established a relatively complete legal system and ethical guidelines. In the design of regulatory responsibilities, a multisectoral linkage of the Ministry of Science and Technology (MOST), the National Health Commission (NHC), the National Medical Products Administration (NMPA), and the National Intellectual Property Administration (CNIPA) has been formed. In the supervision system, it includes a three-tier structure of Laws/Acts-Regulations-Guidance. In terms of management content, it mainly draws on the basic principles of international conventions such as the Convention on Biological Diversity (CBD), and implements examination and approval filing management and ethical supervision of HGR research in China.

9 October 2014 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
WLWei Li
Wei Li
LCLiSheng Cai
LiSheng Cai